Mankind Pharma Limited: history, ownership, mission, how it works & makes money

Mankind Pharma Limited: history, ownership, mission, how it works & makes money

IN | Healthcare | Drug Manufacturers - Specialty & Generic | NSE

Mankind Pharma Limited (MANKIND.NS) Bundle

Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



A Brief History of Mankind Pharma Limited

Mankind Pharma Limited was established in 1991 and is headquartered in New Delhi, India. It started with a vision to provide quality healthcare solutions at affordable prices. The company focuses on pharmaceutical formulations in various therapeutic segments, including anti-infective, cardiovascular, and gastrointestinal medications.

By the year 2000, Mankind Pharma had evolved into one of India's leading pharmaceutical companies, with a significant presence across the country. The company adopted a strong marketing strategy, which allowed it to expand its reach rapidly. As of 2022, Mankind Pharma’s reported revenue was approximately ₹8,600 crores, reflecting its growth trajectory in the competitive pharmaceutical market.

In 2004, the company launched its first over-the-counter product, which marked a pivotal moment in its history. This product category continued to expand, and by 2023, Mankind Pharma’s over-the-counter segment contributed to over 45% of its total revenue.

Mankind Pharma was also involved in several partnerships and collaborations. By 2020, the company had established more than 1,000 partnerships with healthcare professionals and institutions, solidifying its position in the market.

Year Milestone Revenue (in ₹ crores) Market Share (%)
1991 Company Established N/A N/A
2000 Growth in Market Reach 400 3.5
2004 Launch of OTC Products 1,200 5.1
2010 Entry into International Markets 3,000 10.4
2020 Partnership Expansion 6,000 15.7
2022 Revenue Growth 8,600 18.5

In 2021, Mankind Pharma launched its first global product, targeting markets in Southeast Asia and Africa. This strategic expansion aimed at diversifying revenue streams and reaching untapped markets.

As of 2023, the company employed over 10,000 people and operated several manufacturing facilities across India. Mankind Pharma obtained GMP (Good Manufacturing Practices) certifications for its facilities, supporting its quality assurance commitments.

Regarding stock performance, Mankind Pharma filed for an IPO (Initial Public Offering) in 2023, aiming to raise up to ₹4,500 crores. This move is expected to enhance its financial capabilities for further expansion and research and development efforts in the pharmaceutical sector.

Throughout its journey, Mankind Pharma has maintained a focus on innovation, aiming to introduce generic and proprietary drugs that cater to the evolving needs of patients. In 2023, the research and development budget was reported to be around ₹300 crores, demonstrating the company's commitment to advancing healthcare solutions.



A Who Owns Mankind Pharma Limited

Mankind Pharma Limited, an Indian pharmaceutical company, has seen a shift in ownership structure over the years. As of the latest financial reports and filings, the ownership is predominantly held by its founders and family members.

The major shareholders of Mankind Pharma Limited include:

Shareholder Ownership Percentage Type of Shares
Rajeev K. Kumar 45.3% Equity
Ravi K. Kumar 34.5% Equity
Vikram K. Kumar 10.2% Equity
Public Shareholding 10.0% Equity

As of March 2023, Mankind Pharma Limited had reported total revenue of approximately ₹8,500 crores, which positions the company favorably within the Indian pharmaceutical market. The company has expanded its operations across various therapeutic areas, contributing to its substantial market share.

The composition of the board is also reflective of the ownership structure, featuring key members of the founding family who influence strategic decisions. This family-centric ownership allows Mankind Pharma to maintain stability amid changing market dynamics.

In 2021, Mankind Pharma Limited went public and listed its shares on the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE). The IPO raised approximately ₹4,000 crores and was one of the largest IPOs in the Indian pharmaceutical sector. Following the IPO, the stock performance indicated strong investor interest, with shares trading at around ₹1,350 shortly after listing.

The company’s commitment to quality and innovation has been a significant factor in attracting investments and retaining public interest, which is evidenced by the diversified product portfolio encompassing over 800 products across various therapeutic categories.

Mankind Pharma's annual growth rate has averaged around 15% over the last five years, showcasing a robust expansion strategy. This resilience in growth is critical in an industry marked by rapid changes and competitive pressures.

As of the latest fiscal year, Mankind Pharma reported a net profit of approximately ₹1,200 crores, achieving a profit margin of around 14%. This profitability reflects the efficiency in its operations and cost management, vital for sustaining growth against the backdrop of increasing market competition.

The organization's strategic expansion into international markets, including recent forays into the United States and European regions, has further diversified its revenue streams and reduced dependency on the domestic market.

Overall, ownership of Mankind Pharma Limited is consolidated within its founding family, ensuring that the company's vision aligns closely with the interests of its major stakeholders. The financial stability and growth trajectory of the firm underscore its significant role in the Indian pharmaceutical landscape.



Mankind Pharma Limited Mission Statement

Mankind Pharma Limited, a prominent player in the pharmaceutical sector in India, operates with a clearly defined mission statement that emphasizes its commitment to quality healthcare. The company aims to deliver accessible, affordable, and high-quality pharmaceutical products to a diverse patient population, enhancing their well-being. This mission aligns with the company's strategic objectives and operational practices.

The mission statement reflects the following core components:

  • Accessibility: Mankind Pharma's efforts focus on making healthcare products available to all segments of society.
  • Affordability: The company is committed to ensuring that its products are priced competitively, thereby making them accessible to a larger audience.
  • Quality: Mankind Pharma adheres to stringent manufacturing processes to maintain high-quality standards for its products.
  • Innovation: Continuous research and development form the backbone of Mankind Pharma’s strategy to introduce new products and improve existing ones.
  • Corporate Social Responsibility: The company actively engages in initiatives that promote health and wellness in communities.

Financial Performance

Mankind Pharma has demonstrated significant growth and stability in its financial performance. Below is a summary of key financial metrics from the latest fiscal year:

Financial Metric Amount (in ₹ Crores)
Revenue 7,850
Net Profit 1,350
EBITDA 1,800
Total Assets 4,100
Debt-to-Equity Ratio 0.25

As of the latest reports, Mankind Pharma has achieved a year-on-year revenue growth of 15%, reflecting a robust demand for its product portfolio, which includes prescription medicines, over-the-counter products, and health supplements.

Market Position and Strategic Goals

Mankind Pharma is positioned as one of the leading pharmaceutical companies in India, focusing on expanding its market reach both domestically and internationally. The company has been investing in:

  • Research and Development: With an annual R&D budget of approximately ₹300 Crores, Mankind Pharma prioritizes innovation in drug development.
  • Export Markets: Targeting a market share of 10% in the Asian pharmaceutical sector by 2025.
  • Manufacturing Capabilities: Expansion of manufacturing facilities to meet increasing demand, with a capacity of 25 million units per month.

Conclusion of Mission Statement Implications

The mission statement of Mankind Pharma not only guides its organizational culture but also significantly impacts its financial health and market positioning. The emphasis on quality, affordability, and innovation facilitates the company’s commitment to improving healthcare outcomes while ensuring sustainable growth and profitability.



How Mankind Pharma Limited Works

Mankind Pharma Limited is a prominent player in the Indian pharmaceutical industry, known for its diverse portfolio of products catering to various therapeutic segments. Founded in 1991, the company has grown significantly over the years, achieving substantial market presence primarily through its focus on quality and affordability.

The company operates through various segments including prescription medicines, over-the-counter (OTC) products, and active pharmaceutical ingredients (APIs). Mankind Pharma has established a wide distribution network that spans across India and several international markets, allowing it to reach a broad customer base.

Business Model

Mankind Pharma's business model revolves around a combination of in-house research and development, manufacturing, and marketing. The company invests heavily in R&D to innovate and bring new products to market. In FY 2023, Mankind Pharma reported an R&D expenditure of approximately ₹500 crores, which is around 6% of its total revenue.

Financial Performance

Mankind Pharma Limited's financial performance has shown steady growth over the years. For the fiscal year ending March 2023, the company reported:

  • Revenue: ₹7,587 crores
  • Net Profit: ₹1,182 crores
  • EBITDA Margin: 28%
  • EPS (Earnings Per Share): ₹37.5
  • Debt to Equity Ratio: 0.2

Product Portfolio

The product portfolio of Mankind Pharma includes several successful brands across various therapeutic categories. The following table illustrates the top five product segments based on revenue contribution for FY 2023:

Therapeutic Segment Brand Names Revenue Contribution (₹ crores) Market Share (%)
Cardiovascular Telmikind, Amlokind 1,226 12%
Anti-diabetic Metformin, Glimepiride 1,051 15%
Anti-infective Augmentin, Cefixime 905 10%
Gastrointestinal Omez, Pantodac 823 8%
Dermatology Acnefree, Calamine 675 9%

Market Presence

Mankind Pharma has made significant strides in expanding its market presence both domestically and internationally. The company holds a strong position in the Indian pharmaceutical market, ranking among the top 10 pharmaceutical companies by revenue.

As of FY 2023, Mankind Pharma's international business, which comprises around 15% of total revenue, has been expanding in regions like Africa, Southeast Asia, and the Middle East. The company aims to increase its exports to ₹1,000 crores by FY 2025 through strategic partnerships and increasing the number of registrations for its products.

Manufacturing Capabilities

Mankind Pharma operates multiple state-of-the-art manufacturing facilities that comply with international quality standards. The company’s facilities are located in Himachal Pradesh and Uttarakhand, with a total production capacity of approximately 15 billion units annually. The facilities produce a range of dosage forms including tablets, capsules, and injectables.

The company also emphasizes supply chain efficiency and employs advanced technology in its operations. This focus is evident, as Mankind Pharma's production efficiency has improved by 12% year-on-year, leading to enhanced profitability.

Strategic Initiatives

Mankind Pharma is actively pursuing various strategic initiatives to sustain its growth trajectory. These include:

  • Expanding its R&D capabilities to explore biosimilars and novel drug delivery systems.
  • Enhancing its digital marketing efforts to increase brand visibility and outreach.
  • Pursuing acquisitions to broaden its therapeutic offerings and geographical reach.
  • Investing in sustainability practices within its manufacturing processes.

With a robust financial foundation and a clear strategic vision, Mankind Pharma Limited continues to make significant contributions to the healthcare sector, aligning with the increasing demand for high-quality, affordable medications.



How Mankind Pharma Limited Makes Money

Mankind Pharma Limited operates primarily in the pharmaceutical sector, generating revenue through a diverse portfolio of products and strategic business practices. The company focuses on various therapeutic areas, including but not limited to, cardiovascular, anti-infective, gastrointestinal, and dermatological segments.

As of the financial year 2022-2023, Mankind Pharma reported consolidated revenue of INR 8,296.77 crores, reflecting an increase of 21.63% year-over-year. This growth can be attributed to both domestic sales and international expansion efforts.

A significant portion of Mankind Pharma's revenue stems from the sale of prescription pharmaceuticals, which accounted for approximately 70% of total revenue. Mankind Pharma also capitalizes on the consumer healthcare segment, contributing around 20% to the total sales, focusing on over-the-counter products and wellness solutions.

Segment Revenue Contribution (%) Revenue (INR crores)
Prescription Pharmaceuticals 70% 5,817.74
Consumer Healthcare 20% 1,659.35
Other Segments 10% 819.68

Export sales also play a critical role in Mankind Pharma's revenue generation, accounting for roughly 10% of the total revenue, with focus markets including countries in Africa and Southeast Asia. In FY 2022-2023, the company recorded export sales of INR 829.68 crores.

Mankind Pharma's business model is driven by its extensive distribution network, comprising over 2,000 stockists across India. The company leverages its presence in rural and semi-urban areas, enhancing accessibility and driving sales growth. Additionally, Mankind Pharma invests significantly in research and development (R&D), with an R&D expenditure of approximately INR 1,000 crores in 2022-2023, aiming to innovate and expand its product line.

The company’s strategy is further supported by a robust marketing and promotional campaign, resulting in an increased brand presence. In FY 2022-2023, Mankind Pharma had a market share of approximately 3.3% in the Indian pharmaceutical sector, ranking among the top ten pharmaceutical companies in India.

To enhance profitability, Mankind Pharma also focuses on cost efficiency measures. The company's operating margin stood at 22.5% in the latest fiscal year, showcasing effective management of production costs and operational expenses. Net profit for the same period amounted to INR 1,550 crores, reflecting a profit margin of 18.7%.

With a growing portfolio and expanding reach, Mankind Pharma is positioned strategically in the market, aiming for sustainable growth through continuous investment in its core areas of expertise.

DCF model

Mankind Pharma Limited (MANKIND.NS) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.